Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-05-2013 | Review Article

When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET?

Authors: Gang Cheng, Drew A. Torigian, Hongming Zhuang, Abass Alavi

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2013

Abstract

FDG PET and PET/CT are now widely used in oncological imaging for tumor characterization, staging, restaging, and response evaluation. However, numerous benign etiologies may cause increased FDG uptake indistinguishable from that of malignancy. Multiple studies have shown that dual time-point imaging (DTPI) of FDG PET may be helpful in differentiating malignancy from benign processes. However, exceptions exist, and some studies have demonstrated significant overlap of FDG uptake patterns between benign and malignant lesions on delayed time-point images. In this review, we summarize our experience and opinions on the value of DTPI and delayed time-point imaging in oncology, with a review of the relevant literature. We believe that the major value of DTPI and delayed time-point imaging is the increased sensitivity due to continued clearance of background activity and continued FDG accumulation in malignant lesions, if the same diagnostic criteria (as in the initial standard single time-point imaging) are used. The specificity of DTPI and delayed time-point imaging depends on multiple factors, including the prevalence of malignancies, the patient population, and the cut-off values (either SUV or retention index) used to define a malignancy. Thus, DTPI and delayed time-point imaging would be more useful if performed for evaluation of lesions in regions with significant background activity clearance over time (such as the liver, the spleen, the mediastinum), and if used in the evaluation of the extent of tumor involvement rather than in the characterization of the nature of any specific lesion. Acute infectious and non-infectious inflammatory lesions remain as the major culprit for diminished diagnostic performance of these approaches (especially in tuberculosis-endemic regions). Tumor heterogeneity may also contribute to inconsistent performance of DTPI. The authors believe that selective use of DTPI and delayed time-point imaging will improve diagnostic accuracy and interpretation confidence in FDG PET imaging.

Cheng G, Alavi A, Zhuang H. Clinical application of FDG PET/CT in pediatric lymphoma patients. PET Clin. 2012;7:47–56.CrossRef

Hustinx R, Smith RJ, Benard F, Rosenthal DI, Machtay M, Farber LA, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med. 1999;26:1345–8.PubMedCrossRef

Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412–7.PubMed

Kumar R, Loving VA, Chauhan A, Zhuang H, Mitchell S, Alavi A. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. J Nucl Med. 2005;46:1819–24.PubMed

Mavi A, Urhan M, Yu JQ, Zhuang H, Houseni M, Cermik TF, et al. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med. 2006;47:1440–6.PubMed

Xiu Y, Bhutani C, Dhurairaj T, Yu JQ, Dadparvar S, Reddy S, et al. Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity. Clin Nucl Med. 2007;32:101–5.PubMedCrossRef

Alkhawaldeh K, Bural G, Kumar R, Alavi A. Impact of dual-time-point (18)F-FDG PET imaging and partial volume correction in the assessment of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging. 2008;35:246–52.PubMedCrossRef

Schillaci O, Travascio L, Bolacchi F, Calabria F, Bruni C, Ciccio C, et al. Accuracy of early and delayed FDG PET-CT and of contrast-enhanced CT in the evaluation of lung nodules: a preliminary study on 30 patients. Radiol Med. 2009;114:890–906.PubMedCrossRef

Lee JW, Kim SK, Lee SM, Moon SH, Kim TS. Detection of hepatic metastases using dual-time-point FDG PET/CT scans in patients with colorectal cancer. Mol Imaging Biol. 2011;13:565–72.PubMedCrossRef

10.

Shinya T, Fujii S, Asakura S, Taniguchi T, Yoshio K, Alafate A, et al. Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma. Ann Nucl Med. 2012;26:616–21.PubMedCrossRef

11.

Gallagher BM, Ansari A, Atkins H, Casella V, Christman DR, Fowler JS, et al. Radiopharmaceuticals XXVII. 18F-labeled 2-deoxy-2-fluoro-d-glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo: tissue distribution and imaging studies in animals. J Nucl Med. 1977;18:990–6.PubMed

12.

Chang CC, Cho SF, Chen YW, Tu HP, Lin CY, Chang CS. SUV on dual-phase FDG PET/CT correlates with the Ki-67 proliferation index in patients with newly diagnosed non-Hodgkin lymphoma. Clin Nucl Med. 2012;37:e189–95.PubMedCrossRef

13.

Higashi T, Saga T, Nakamoto Y, Ishimori T, Mamede MH, Wada M, et al. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43:173–80.PubMed

14.

Chen CJ, Lee BF, Yao WJ, Cheng L, Wu PS, Chu CL, et al. Dual-phase 18F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5. AJR Am J Roentgenol. 2008;191:475–9.PubMedCrossRef

15.

Yen R-F, Chen K-C, Lee J-M, Chang Y-C, Wang J, Cheng M-F, et al. 18F-FDG PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: is dual time point imaging worth the effort? Eur J Nucl Med Mol Imaging. 2008;35:1305–15.PubMedCrossRef

16.

Laffon E, de Clermont H, Begueret H, Vernejoux J-M, Thumerel M, Marthan R, et al. Assessment of dual-time-point 18F-FDG-PET imaging for pulmonary lesions. Nucl Med Commun. 2009;30:455–61.PubMedCrossRef

17.

Sathekge MM, Maes A, Pottel H, Stoltz A, van de Wiele C. Dual time-point FDG PET-CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area. S Afr Med J. 2010;100:598–601.PubMed

18.

Kim DW, Kim CG. Dual-time point positron emission tomography findings of benign mediastinal lymph nodes in a tuberculosis-endemic region. Jpn J Radiol. 2011;29:682–7.PubMedCrossRef

19.

Umeda Y, Demura Y, Morikawa M, Ameshima S, Tsuchida T, Fujibayashi Y, et al. Prognostic value of dual-time-point 18F-fluorodeoxyglucose positron emission tomography in patients with pulmonary sarcoidosis. Respirology. 2011;16:713–20.PubMedCrossRef

20.

Li M, Wu N, Liu Y, Zheng R, Liang Y, Zhang W, et al. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: additional diagnostic value of CT attenuation and dual-time-point imaging. Eur J Radiol. 2012;81:1886–90.PubMedCrossRef

21.

Zheng Z, Pan Y, Guo F, Wei H, Wu S, Pan T, et al. Multimodality FDG PET/CT appearance of pulmonary tuberculoma mimicking lung cancer and pathologic correlation in a tuberculosis-endemic country. South Med J. 2011;104:440–5.PubMedCrossRef

22.

Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47:885–95.PubMed

23.

Dirisamer A, Halpern BS, Schima W, Heinisch M, Wolf F, Beheshti M, et al. Dual-time-point FDG-PET/CT for the detection of hepatic metastases. Mol Imaging Biol. 2008;10:335–40.PubMedCrossRef

24.

Alkhawaldeh K, Biersack HJ, Henke A, Ezziddin S. Impact of dual-time-point F-18 FDG PET/CT in the assessment of pleural effusion in patients with non-small-cell lung cancer. Clin Nucl Med. 2011;36:423–8.PubMedCrossRef

25.

Hahn S, Hecktor J, Grabellus F, Hartung V, Poppel T, Kimmig R, et al. Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients. Acta Radiol. 2012;53:518–23.PubMedCrossRef

26.

Ma SY, See LC, Lai CH, Chou HH, Tsai CS, Ng KK, et al. Delayed (18)F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients. J Nucl Med. 2003;44:1775–83.PubMed

27.

Demura Y, Tsuchida T, Ishizaki T, Mizuno S, Totani Y, Ameshima S, et al. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med. 2003;44:540–8.PubMed

28.

Yen TC, Chang YC, Chan SC, Chang JT, Hsu CH, Lin KJ, et al. Are dual-phase 18F-FDG PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and loco-regional nodes? Eur J Nucl Med Mol Imaging. 2005;32:541–8.PubMedCrossRef

29.

Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med. 2002;43:871–5.PubMed

30.

Lan XL, Zhang YX, Wu ZJ, Jia Q, Wei H, Gao ZR. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions. Clin Radiol. 2008;63:756–64.PubMedCrossRef

31.

Nishiyama Y, Yamamoto Y, Kimura N, Ishikawa S, Sasakawa Y, Ohkawa M. Dual-time-point FDG-PET for evaluation of lymph node metastasis in patients with non-small-cell lung cancer. Ann Nucl Med. 2008;22:245–50.PubMedCrossRef

32.

Kim SJ, Kim YK, Kim IJ, Kim YD, Lee MK. Limited predictive value of dual-time-point F-18 FDG PET/CT for evaluation of pathologic N1 status in NSCLC patients. Clin Nucl Med. 2011;36:434–9.PubMedCrossRef

33.

Hu M, Han A, Xing L, Yang W, Fu Z, Huang C, et al. Value of dual-time-point FDG PET/CT for mediastinal nodal staging in non-small-cell lung cancer patients with lung comorbidity. Clin Nucl Med. 2011;36:429–33.PubMedCrossRef

34.

Nakamura S, Okochi K, Kurabayashi T. Dual-time-point fluorodeoxyglucose positron emission tomography for diagnosis of cervical lymph node metastases in patients with head and neck squamous cell carcinoma. J Comput Assist Tomogr. 2011;35:303–7.PubMedCrossRef

35.

Cloran FJ, Banks KP, Song WS, Kim Y, Bradley YC. Limitations of dual time point PET in the assessment of lung nodules with low FDG avidity. Lung Cancer. 2010;68:66–71.PubMedCrossRef

36.

Hu Q, Wang W, Zhong X, Yuan S, Fu Z, Guo H, et al. Dual-time-point FDG PET for the evaluation of locoregional lymph nodes in thoracic esophageal squamous cell cancer. Eur J Radiol. 2009;70:320–4.PubMedCrossRef

37.

Kim SJ, Kim YK, Kim IJ, Kim YD, Lee MK. Limited prognostic value of dual time point F-18 FDG PET/CT in patients with early stage (stage I & II) non-small cell lung cancer (NSCLC). Radiother Oncol. 2011;98:105–8.PubMedCrossRef

38.

Suga K, Kawakami Y, Hiyama A, Sugi K, Okabe K, Matsumoto T, et al. Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions. Ann Nucl Med. 2009;23:427–35.PubMedCrossRef

39.

Macdonald K, Searle J, Lyburn I. The role of dual time point FDG PET imaging in the evaluation of solitary pulmonary nodules with an initial standard uptake value less than 2.5. Clin Radiol. 2011;66:244–50.PubMedCrossRef

40.

Suga K, Kawakami Y, Hiyama A, Matsunaga N. Differentiation of FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer with dual-time point F-18-fluorodeoxy-glucose PET/CT scan. Ann Nucl Med. 2009;23:399–407.PubMedCrossRef

41.

Suga K, Kawakami Y, Hiyama A, Sugi K, Okabe K, Matsumoto T, et al. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan. Ann Nucl Med. 2009;23:523–31.PubMedCrossRef

42.

Sanghera B, Wong WL, Lodge MA, Hain S, Stott D, Lowe J, et al. Potential novel application of dual time point SUV measurements as a predictor of survival in head and neck cancer. Nucl Med Commun. 2005;26:861–7.PubMedCrossRef

43.

Basu S, Mavi A, Cermik T, Houseni M, Alavi A. Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: does 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography predict tumor biology? Mol Imaging Biol. 2008;10:62–6.PubMedCrossRef

44.

Tian R, Su M, Tian Y, Li F, Li L, Kuang A, et al. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions. Skeletal Radiol. 2009;38:451–8.PubMedCrossRef

45.

Kim DW, Jung SA, Kim CG, Park SA. The efficacy of dual time point F-18 FDG PET imaging for grading of brain tumors. Clin Nucl Med. 2010;35:400–3.PubMedCrossRef

46.

Fuster D, Lafuente S, Setoain X, Navales I, Perissinotti A, Pavia J, et al. Dual-time point images of the liver with (18)F-FDG PET/CT in suspected recurrence from colorectal cancer. Rev Esp Med Nucl. 2012;31:111–6.

47.

Kubota K, Yokoyama J, Yamaguchi K, Ono S, Qureshy A, Itoh M, et al. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. Eur J Nucl Med Mol Imaging. 2004;31:590–5.PubMedCrossRef

48.

Fischman AJ, Alpert NM. FDG-PET in oncology: there’s more to it than looking at pictures [editorial]. J Nucl Med. 1993;34:6–11.PubMed

49.

Lowe VJ, DeLong DM, Hoffman JM, Coleman RE. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med. 1995;36:883–7.PubMed

50.

Kubota K, Itoh M, Ozaki K, Ono S, Tashiro M, Yamaguchi K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med. 2001;28:696–703.PubMedCrossRef

51.

Nishiyama Y, Yamamoto Y, Fukunaga K, Kimura N, Miki A, Sasakawa Y, et al. Dual-time-point 18F-FDG PET for the evaluation of gallbladder carcinoma. J Nucl Med. 2006;47:633–8.PubMed

52.

Arena V, Skanjeti A, Casoni R, Douroukas A, Pelosi E. Dual-phase FDG-PET: delayed acquisition improves hepatic detectability of pathological uptake. Radiol Med. 2008;113:875–86.PubMedCrossRef

53.

Cheng G, Alavi A, Lim E, Werner TJ, Del Bello CV, Akers SR. Dynamic changes of FDG uptake and clearance in normal tissues. Mol Imaging Biol. 2012. doi:10.1007/s11307-012-0600-0.

54.

Gupta N, Gill H, Graeber G, Bishop H, Hurst J, Stephens T. Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions. Chest. 1998;114:1105–11.PubMedCrossRef

55.

Nishiyama Y, Yamamoto Y, Monden T, Sasakawa Y, Tsutsui K, Wakabayashi H, et al. Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour. Nucl Med Commun. 2005;26:895–901.PubMedCrossRef

56.

Chen YM, Huang G, Sun XG, Liu JJ, Chen T, Shi YP, et al. Optimizing delayed scan time for FDG PET: comparison of the early and late delayed scan. Nucl Med Commun. 2008;29:425–30.PubMedCrossRef

57.

Shinya T, Rai K, Okumura Y, Fujiwara K, Matsuo K, Yonei T, et al. Dual-time-point F-18 FDG PET/CT for evaluation of intrathoracic lymph nodes in patients with non-small cell lung cancer. Clin Nucl Med. 2009;34:216–21.PubMedCrossRef

58.

Beaulieu S, Kinahan P, Tseng J, Dunnwald LK, Schubert EK, Pham P, et al. SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences. J Nucl Med. 2003;44:1044–50.PubMed

59.

Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med. 1994;35:1308–12.PubMed

60.

Zytoon AA, Murakami K, El-Kholy MR, El-Shorbagy E. Dual time point FDG-PET/CT imaging… Potential tool for diagnosis of breast cancer. Clin Radiol. 2008;63:1213–27.PubMedCrossRef

61.

Kikuchi M, Nakamoto Y, Shinohara S, Fujiwara K, Tona Y, Yamazaki H, et al. Suture granuloma showing false-positive finding on PET/CT after head and neck cancer surgery. Auris Nasus Larynx. 2012;39:94–7.PubMedCrossRef

62.

Ho L, Wassef H, Seto J. FDG PET/CT imaging in granulomatous changes secondary to breast silicone injection. Clin Radiol. 2010;65:659–61.PubMedCrossRef

63.

Prosch H, Mirzaei S, Oschatz E, Strasser G, Huber M, Mostbeck G. Case report: gluteal injection site granulomas: false positive finding on FDG-PET in patients with non-small cell lung cancer. Br J Radiol. 2005;78:758–61.PubMedCrossRef

64.

Kirsch CFE, Suh JD, Lufkin RB, Canalis RF. False-positive positron-emission tomography-CT of a Teflon granuloma in the parapharyngeal space occurring after treatment for a patulous eustachian tube. AJNR Am J Neuroradiol. 2007;28:1371–2.PubMedCrossRef

65.

Morishita K, Otomo Y, Sasaki H, Yamashiro T, Okubo K. Multiple abdominal granuloma caused by spilled gallstones with imaging findings that mimic malignancy. Am J Surg. 2010;199:e23–4.PubMedCrossRef

66.

Lim ST, Jeong H-J, Kim DW, Yim C-Y, Sohn M-H. F-18 FDG PET-CT findings of intraperitoneal carbon particles-induced granulomas mimicking peritoneal carcinomatosis. Clin Nucl Med. 2008;33:321–4.PubMedCrossRef

67.

Tenconi S, Luzzi L, Paladini P, Voltolini L, Gallazzi MS, Granato F, et al. Pleural granuloma mimicking malignancy 42 years after slurry talc injection for primary spontaneous pneumothorax. Eur Surg Res. 2010;44:201–3.PubMedCrossRef

68.

Miyake KK, Nakamoto Y, Mikami Y, Ishizu K, Saga T, Higashi T, et al. F-18 FDG PET of foreign body granuloma: pathologic correlation with imaging features in 3 cases. Clin Nucl Med. 2010;35:853–7.PubMedCrossRef

69.

Cheng G, Torigian DA, Alavi A. FDG PET/CT and MRI findings in a patient with focal xanthogranulomatous pyelonephritis mimicking cystic renal malignancy. Clin Nephrol. 2011;76:484–6.PubMed

70.

Makino I, Yamaguchi T, Sato N, Yasui T, Kita I. Xanthogranulomatous cholecystitis mimicking gallbladder carcinoma with a false-positive result on fluorodeoxyglucose PET. World J Gastroenterol. 2009;15:3691–3.PubMedCrossRef

71.

Li Y-J, Zhang Y, Gao S, Bai R-J. Cervical and axillary lymph node sarcoidosis misdiagnosed as lymphoma on F-18 FDG PET-CT. Clin Nucl Med. 2007;32:262–4.PubMedCrossRef

72.

Cheng C-Y, Huang W-S, Shen DH, Fan Y-M, Hsu H-H, Cherng S-C, et al. FDG PET/CT demonstrated rapid progression of mediastinal lymphadenopathy in sarcoidosis. Clin Nucl Med. 2007;32:117–21.PubMedCrossRef

73.

Prabhakar HB, Rabinowitz CB, Gibbons FK, O’Donnell WJ, Shepard J-AO, Aquino SL. Imaging features of sarcoidosis on MDCT, FDG PET, and PET/CT. AJR Am J Roentgenol. 2008;190:S1–6.PubMedCrossRef

74.

Razak HR, Geso M, Abdul Rahim N, Nordin AJ. Imaging characteristics of extrapulmonary tuberculosis lesions on dual time point imaging (DTPI) of FDG PET/CT. J Med Imaging Radiat Oncol. 2011;55:556–62.PubMedCrossRef

75.

Nunez R, Kalapparambath A, Varela J. Improvement in sensitivity with delayed imaging of pulmonary lesions with FDG-PET. Rev Esp Med Nucl. 2007;26:196–207.PubMedCrossRef

76.

Basu S, Kwee TC, Gatenby R, Saboury B, Torigian DA, Alavi A. Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders. Eur J Nucl Med Mol Imaging. 2011;38:987–91.PubMedCrossRef

77.

Asselin M-C, O’Connor JPB, Boellaard R, Thacker NA, Jackson A. Quantifying heterogeneity in human tumours using MRI and PET. Eur J Cancer. 2012;48:447–55.PubMedCrossRef

78.

Beresford M, Sanghera B, Wong W-L, Makris A. Imaging of primary breast cancer with 18F-fluorodeoxythymidine PET-CT reveals heterogeneity of proliferation throughout the tumour. Eur J Nucl Med Mol Imaging. 2006;33:624.PubMedCrossRef

79.

Sorensen M, Horsman MR, Cumming P, Munk OL, Keiding S. Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and electrode PO2 measurements in murine tumors. Int J Radiat Oncol Biol Phys. 2005;62:854–61.PubMedCrossRef

80.

Wyss MT, Hofer S, Hefti M, Bartschi E, Uhlmann C, Treyer V, et al. Spatial heterogeneity of low-grade gliomas at the capillary level: a PET study on tumor blood flow and amino acid uptake. J Nucl Med. 2007;48:1047–52.PubMedCrossRef

81.

Hatt M, Cheze-le Rest C, van Baardwijk A, Lambin P, Pradier O, Visvikis D. Impact of tumor size and tracer uptake heterogeneity in (18)F-FDG PET and CT non-small cell lung cancer tumor delineation. J Nucl Med. 2011;52:1690–7.PubMedCrossRef

82.

Spence AM, Muzi M, Mankoff DA, O’Sullivan SF, Link JM, Lewellen TK, et al. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. J Nucl Med. 2004;45:1653–9.PubMed

83.

Prieto E, Marti-Climent JM, Dominguez-Prado I, Garrastachu P, Diez-Valle R, Tejada S, et al. Voxel-based analysis of dual-time-point 18F-FDG PET images for brain tumor identification and delineation. J Nucl Med. 2011;52:865–72.PubMedCrossRef

84.

Horky LL, Hsiao EM, Weiss SE, Drappatz J, Gerbaudo VH. Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis. J Neurooncol. 2011;103:137–46.PubMedCrossRef

85.

Chin BB, Green ED, Turkington TG, Hawk TC, Coleman RE. Increasing uptake time in FDG-PET: standardized uptake values in normal tissues at 1 versus 3 h. Mol Imaging Biol. 2009;11:118–22.PubMedCrossRef

86.

Deppen S, Putnam Jr JB, Andrade G, Speroff T, Nesbitt JC, Lambright ES, et al. Accuracy of FDG-PET to diagnose lung cancer in a region of endemic granulomatous disease. Ann Thorac Surg. 2011;92:428–32.PubMedCrossRef

87.

Alavi A, Gupta N, Alberini J-L, Hickeson M, Adam L-E, Bhargava P, et al. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med. 2002;32:293–321.PubMedCrossRef

88.

Conrad GR, Sinha P. Narrow time-window dual-point 18F-FDG PET for the diagnosis of thoracic malignancy. Nucl Med Commun. 2003;24:1129–37.PubMedCrossRef

89.

Uesaka D, Demura Y, Ishizaki T, Ameshima S, Miyamori I, Sasaki M, et al. Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer. J Nucl Med. 2008;49:1606–12.PubMedCrossRef

90.

Lin W-Y, Tsai S-C, Hung G-U. Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma. Nucl Med Commun. 2005;26:315–21.PubMedCrossRef

91.

Nishiyama Y, Yamamoto Y, Kimura N, Miki A, Sasakawa Y, Wakabayashi H, et al. Comparison of early and delayed FDG PET for evaluation of biliary stricture. Nucl Med Commun. 2007;28:914–9.PubMedCrossRef

92.

Kim SJ, Kim BH, Jeon YK, Kim SS, Kim IJ. Limited diagnostic and predictive values of dual-time-point 18F FDG PET/CT for differentiation of incidentally detected thyroid nodules. Ann Nucl Med. 2011;25:347–53.PubMedCrossRef

93.

Hsiao YC, Wu PS, Chiu NT, Yao WJ, Lee BF, Peng SL. The use of dual-phase 18F-FDG PET in characterizing thyroid incidentalomas. Clin Radiol. 2011;66:1197–202.PubMedCrossRef

Title: When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET?
Authors: Gang Cheng
Drew A. Torigian
Hongming Zhuang
Abass Alavi
Publication date: 01-05-2013
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2013
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-013-2343-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET?

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2013

Correlation between [18F]FDG PET/CT and volume perfusion CT in primary tumours and mediastinal lymph nodes of non-small-cell lung cancer

Sensitivity of PET/MRI to detect recurrence of prostate cancer

Comment on Mertens et al.: standardized added metabolic activity (SAM): a partial volume independent marker of total lesion glycolysis in liver metastases

Nuclear medicine training and practice in Austria

Evaluation of intratumoural heterogeneity on 18F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1

Gary Liney (ed): MRI from A to Z: a Definitive Guide for Medical Professionals